Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors

Key Points

• To examine the relationship between histological subtypes and treatment response in non-small cell lung cancer patients.
• Analyzed the response of NSCC-NOS subtype to PD-1/PD-L1 inhibitors
• Compared outcomes with and without chemotherapy
• NSCC-NOS subtype shows high responsiveness to first-line PD-1/PD-L1 inhibitors
• Patient outcomes improve notably with NSCC-NOS when treated with immune checkpoint inhibitors